76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Cogent Biosciences Inc
Open
11.05 0.73
Overview
Share price change
24h
Min
10.64
Max
11.17
Income | -4.1M -72M |
|---|---|
Employees | 205 |
EBITDA | -1.2M -74M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +69.76% upside |
Next Earnings | 5 Aug 2025 |
|---|
Market Cap | 430M 1.1B |
|---|---|
Previous open | 10.32 |
Previous close | 11.05 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Cogent Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cogent Biosciences Inc Forecast
Price Target
By TipRanks
69.76% upside
12 Months Forecast
Average 18.64 USD 69.76%
High 28 USD
Low 9 USD
Based on 12 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
